Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00788892 | Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | completed | Phase 2 | 126 | Jazz PharmaceuticalsINDUSTRY | 2 | Jan 12, 2018 | clinicaltrials |
| NCT00541866 | Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans | completed | Phase 1 / Phase 2 | 110 | Sunesis PharmaceuticalsINDUSTRY | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00867529 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
| completed |
| Phase 2 |
| 63 |
| Fred Hutchinson Cancer CenterOTHER |
| 1 |
| Jan 2, 2018 |
| clinicaltrials |
| NCT00303667 | Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 50 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00098839 | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 134 | Children's Oncology GroupNETWORK | 4 | Dec 12, 2017 | clinicaltrials |
| NCT00822094 | Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | completed | Phase 2 | 126 | Jazz PharmaceuticalsINDUSTRY | 4 | Nov 24, 2017 | clinicaltrials |
| NCT01101880 | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | completed | Phase 2 | 50 | University of WashingtonOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01457040 | Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(BSTPHASE1-01) | completed | Phase 1 / Phase 2 | 20 | BioSight Ltd.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 / Phase 3 | 920 | University of UlmOTHER | 2 | Sep 20, 2017 | clinicaltrials |
| NCT01116193 | Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia(RV-405 LAL) | completed | Phase 2 | 10 | Institut de Cancérologie de la LoireOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT00005940 | Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission | completed | Phase 2 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01947322 | Haploidentical NK-cell Infusion in Acute Myeloid Leukemia(NK) | completed | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01141725 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | completed | Phase 1 / Phase 2 | 39 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01466179 | Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 225 | Amgen Research (Munich) GmbHINDUSTRY | 6 | Aug 18, 2017 | clinicaltrials |
| NCT01606579 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 49 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01349972 | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 172 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00186875 | Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 47 | St. Jude Children's Research HospitalOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00462605 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2017 | clinicaltrials |
| NCT01643668 | Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00839982 | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00607997 | Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia | completed | Phase 2 | 113 | Sunesis PharmaceuticalsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00854945 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | completed | Phase 1 / Phase 2 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00145626 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | completed | Phase 2 | 40 | St. Jude Children's Research HospitalOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00687323 | Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)(TALL) | completed | Phase 2 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00003875 | Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01457885 | Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen(CloBu4) | completed | Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT01083706 | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT01435343 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | completed | Phase 1 / Phase 2 | 55 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01363297 | Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia | completed | Phase 2 | 72 | PfizerINDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT00973752 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01209286 | Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 36 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00880269 | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 23, 2017 | clinicaltrials |
| NCT00475150 | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01567059 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 34 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00394381 | Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 17 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 12, 2018source: clinicaltrials